VIVA Biotech Holdings
HKEX:1873
Intrinsic Value
Viva Biotech Holdings engages in preclinical research and development of innovative drugs. [ Read More ]
The intrinsic value of one VIVA Biotech Holdings stock under the Base Case scenario is 2.865 HKD. Compared to the current market price of 0.415 HKD, VIVA Biotech Holdings is Undervalued by 86%.
Valuation Backtest
VIVA Biotech Holdings
Run backtest to discover the historical profit from buying and selling VIVA Biotech Holdings stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
VIVA Biotech Holdings
| Current Assets | 2.2B |
| Cash & Short-Term Investments | 1.1B |
| Receivables | 345.2m |
| Other Current Assets | 752.4m |
| Non-Current Assets | 6B |
| Long-Term Investments | 1.1B |
| PP&E | 1.9B |
| Intangibles | 2.6B |
| Other Non-Current Assets | 361.5m |
| Current Liabilities | 3.2B |
| Accounts Payable | 281.4m |
| Accrued Liabilities | 156.5m |
| Other Current Liabilities | 2.7B |
| Non-Current Liabilities | 1.4B |
| Long-Term Debt | 619.1m |
| Other Non-Current Liabilities | 734.8m |
Earnings Waterfall
VIVA Biotech Holdings
|
Revenue
|
2.4B
CNY
|
|
Cost of Revenue
|
-1.5B
CNY
|
|
Gross Profit
|
876.7m
CNY
|
|
Operating Expenses
|
-556.2m
CNY
|
|
Operating Income
|
320.5m
CNY
|
|
Other Expenses
|
-756.8m
CNY
|
|
Net Income
|
-436.3m
CNY
|
Free Cash Flow Analysis
VIVA Biotech Holdings
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
VIVA Biotech Holdings's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
Score
VIVA Biotech Holdings's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
VIVA Biotech Holdings's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Score
VIVA Biotech Holdings's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
VIVA Biotech Holdings
Shareholder Return
Price
VIVA Biotech Holdings
| Average Annual Return | -2.79% |
| Standard Deviation of Annual Returns | 71.08% |
| Max Drawdown | -96% |
| Market Capitalization | 888.8m HKD |
| Shares Outstanding | 2 141 770 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Viva Biotech Holdings engages in preclinical research and development of innovative drugs. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2019-05-09. The firm is principally engaged in the provision of the structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development. The Company’s core technologies include structure-based drug discovery (SBDD) platform, fragment-based drug discovery (FBDD) platform, affinity selection mass spectrometry (ASMS) screening platform and membrane protein targeted drug discovery platform. The firm operates its businesses mainly in the United States, China, Europe and other regions.
Contact
IPO
Employees
Officers
The intrinsic value of one VIVA Biotech Holdings stock under the Base Case scenario is 2.865 HKD.
Compared to the current market price of 0.415 HKD, VIVA Biotech Holdings is Undervalued by 86%.
You don't have any saved screeners yet
